Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Gastrointestinal Stromal Tumors (GISTs) Market Outlook
Thelansis’s “Gastrointestinal Stromal
Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Gastrointestinal Stromal Tumors
(GISTs) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Gastrointestinal
Stromal Tumors (GISTs) Overview
Gastrointestinal
stromal tumors (GISTs) are the most common mesenchymal neoplasms of the
gastrointestinal tract. Approximately 80% of GISTs harbor activating mutations
in the KIT or PDGFRA genes that are
responsible for the upregulation of crucial signaling pathways, including MAPK
and PI3K-AKT. GISTs lacking KIT and PDGFRA mutations
are referred to as “wild-type” (wt)-GISTs. They can develop in the colon,
rectum, esophagus, mesentery, and omentum, but are most commonly found in the
stomach (60%) and small intestine (30%). Fatigue, abdominal pain, dysphagia,
early satiety, and obstruction are common symptoms associated with GISTs. One
or more GISTs develop in approximately 7% of patients with neurofibromatosis
type I (NF1). These NF1-associated GISTs typically arise in the small
intestine, tend to be multiple, and are usually KIT and PDGFRA wild-type,
but often exhibit somatic mutations or loss of the remaining wild-type NF1 allele,
resulting in MAP kinase pathway activation.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment